糖尿病性末梢神経障害の世界市場レポート 2025年

糖尿病性末梢神経障害市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.1％で54億3,000万米ドルに成長します。予測期間中の成長は、座りがちなライフスタイルの増加、政府の取り組みと助成金の増加、神経障害の危険因子の有病率の増加、診断精度の向上、早期発見と予防への支援の拡大に起因すると考えられます。予測期間における主な動向としては、診断技術の発展、治療オプションの革新、研究開発投資の増加、低侵襲手技の開発、共同研究開発への注目の高まりなどが挙げられます。

肥満関連の健康問題の有病率の上昇は、今後数年間の糖尿病性末梢神経障害市場の拡大を促進すると予測されます。肥満は、過剰な体脂肪蓄積を特徴とする病状であり、健康を損ない、慢性疾患のリスクを高める可能性があります。肥満に関連する健康への懸念、ライフスタイルの変化、予防・治療ソリューションへのニーズの高まりに対する意識の高まりが、ヘルスケア需要の拡大に寄与しています。糖尿病性末梢神経障害は、肥満関連疾患によって引き起こされる神経損傷に関する知見を提供し、患者の幸福と生活の質を高めるための的を絞った介入を可能にすることで、肥満管理に重要な役割を果たしています。例えば、2024年3月、スイスに本部を置く世界保健機関（WHO）は、世界の公衆衛生に焦点を当てた国連の専門機関であるが、2022年には18歳以上の成人の43％が太りすぎと分類され、16％が肥満とともに生活していると報告しました。さらに、5歳未満の子供のうち3,700万人が太りすぎで、5歳から19歳の子供と青少年では3億9,000万人以上が太りすぎで、そのうち1億6,000万人が肥満の影響を受けています。その結果、肥満に関連した健康問題の発生率の増加が、糖尿病性末梢神経障害市場の成長を促進しています。

糖尿病性末梢神経障害市場の主要企業は、疼痛管理を改善し患者のQOLを高める革新的な非オピオイド治療を提供するために、NaV1.8疼痛シグナル阻害剤などの技術的進歩を優先しています。NaV1.8疼痛シグナル阻害剤は、感覚ニューロンにおける疼痛シグナルの主要なメディエーターであるNaV1.8ナトリウムチャネルを遮断する特殊な薬剤であり、オピオイドに頼ることなく急性疼痛や神経障害性疼痛の緩和をもたらします。例えば、2024年4月、米国のバイオテクノロジー企業であるバーテックス・ファーマシューティカルズ・インコーポレーテッドは、スゼトリギン疼痛プログラムの進捗状況を発表しました。スゼトリギンは、選択的NaV1.8疼痛シグナル阻害薬であり、先行研究で有望な結果を示し、最近、米国の連邦機関である食品医薬品局（FDA）より、糖尿病性末梢神経障害疼痛管理に対する画期的治療薬の指定を受けた。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界糖尿病性末梢神経障害 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の糖尿病性末梢神経障害市場：成長率分析
• 世界の糖尿病性末梢神経障害市場の実績：規模と成長, 2019-2024
• 世界の糖尿病性末梢神経障害市場の予測：規模と成長, 2024-2029, 2034F
• 世界糖尿病性末梢神経障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病性末梢神経障害市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ2糖尿病性末梢神経障害
• タイプ1糖尿病性末梢神経障害
• 世界の糖尿病性末梢神経障害市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 疼痛管理薬
• 遺伝子治療
• 世界の糖尿病性末梢神経障害市場：セラピー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗うつ薬
• 抗けいれん薬
• 世界の糖尿病性末梢神経障害市場患者集団別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人患者
• 高齢患者
• 世界の糖尿病性末梢神経障害市場2型糖尿病性末梢神経障害の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 感覚神経障害
• 運動神経障害
• 自律神経障害
• 世界の糖尿病性末梢神経障害市場1型糖尿病性末梢神経障害の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遠位対称性ニューロパチー
• 単神経障害
• 多発性神経根障害

第7章 地域別・国別分析

• 世界の糖尿病性末梢神経障害市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の糖尿病性末梢神経障害市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病性末梢神経障害市場：競合情勢
• 糖尿病性末梢神経障害市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Sun Pharmaceutical Industries Limited
• Lupin Pharmaceuticals Inc.
• Chemie Grunenthal GmbH
• Alkem Laboratories Limited
• Acorda Therapeutics Inc.
• Mitsubishi Tanabe Pharma Corporation
• NeuroMetrix Inc.
• Regenacy Pharmaceuticals Inc.
• Helixmith Co. Ltd.
• Aptinyx Inc.
• WinSanTor Inc.
• Sonnet BioTherapeutics Holdings Inc.
• OLYS Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖尿病性末梢神経障害市場2029：新たな機会を提供する国
• 糖尿病性末梢神経障害市場2029：新たな機会を提供するセグメント
• 糖尿病性末梢神経障害市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Diabetic Peripheral Neuropathy (DPN) is a nerve disorder resulting from prolonged high blood sugar levels in individuals with diabetes, causing nerve damage primarily in the legs, feet, arms, and hands. This condition develops due to long-term elevated blood sugar levels, which harm the nerves and blood vessels, leading to impaired nerve function and reduced blood flow to the affected areas.

The primary types of diabetic peripheral neuropathy include type 2 and type 1 diabetic peripheral neuropathy. Type 2 diabetic peripheral neuropathy is a nerve damage condition caused by prolonged high blood sugar levels in individuals with type 2 diabetes, resulting in pain, numbness, and tingling, mainly in the feet and hands. Treatment options encompass pain management drugs and emerging gene therapies, while therapeutic approaches involve the use of antidepressants and anticonvulsants. The affected patient population primarily consists of adult and geriatric individuals.

The diabetic peripheral neuropathy market research report is one of a series of new reports from The Business Research Company that provides diabetic peripheral neuropathy market statistics, including the diabetic peripheral neuropathy industry global market size, regional shares, competitors with the diabetic peripheral neuropathy market share, detailed diabetic peripheral neuropathy market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic peripheral neuropathy industry. This diabetic peripheral neuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetic peripheral neuropathy market size has grown strongly in recent years. It will grow from $3.51 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to the expanding geriatric population, the increasing prevalence of diabetes, rising healthcare expenditure, growing awareness of diabetic complications, and the enhancement of healthcare infrastructure.

The diabetic peripheral neuropathy market size is expected to see strong growth in the next few years. It will grow to $5.43 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the rise in sedentary lifestyles, increased government initiatives and funding, the growing prevalence of neuropathy risk factors, improved diagnostic accuracy, and expanding support for early detection and prevention. Key trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, increased investment in research and development, the development of minimally invasive procedures, and a heightened focus on collaborative research and development.

The rising prevalence of obesity-related health issues is anticipated to drive the expansion of the diabetic peripheral neuropathy market in the coming years. Obesity is a medical condition characterized by excessive body fat accumulation, which can impair health and increase the risk of chronic diseases. The growing awareness of obesity-related health concerns, lifestyle changes, and the increasing need for preventive and treatment solutions have contributed to greater healthcare demand. Diabetic peripheral neuropathy plays a critical role in obesity management by offering insights into nerve damage caused by obesity-related conditions, enabling targeted interventions to enhance patient well-being and quality of life. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations focused on global public health, reported that in 2022, 43% of adults aged 18 and over were classified as overweight, while 16% were living with obesity. Additionally, 37 million children under the age of five were overweight, and among children and adolescents aged 5 to 19 years, over 390 million were overweight, including 160 million affected by obesity. As a result, the increasing incidence of obesity-related health issues is driving growth in the diabetic peripheral neuropathy market.

Leading companies in the diabetic peripheral neuropathy market are prioritizing technological advancements, such as NaV1.8 pain signal inhibitors, to offer innovative non-opioid treatments that improve pain management and enhance patients' quality of life. A NaV1.8 pain signal inhibitor is a specialized drug that blocks the NaV1.8 sodium channel, a key mediator of pain signals in sensory neurons, to provide relief from acute and neuropathic pain without relying on opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, announced progress in its suzetrigine pain program, including the initiation of a Phase 3 pivotal program for treating pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has demonstrated promising results in earlier studies and recently received breakthrough therapy designation from the Food and Drug Administration (FDA), a US-based federal agency, for diabetic peripheral neuropathy pain management.

In December 2024, ElectroCore, Inc., a US-based medical technology company, acquired NeuroMetrix, Inc. for $26 million. This acquisition aims to expand ElectroCore's bioelectronic health and wellness portfolio by integrating NeuroMetrix's Quell platform. The strategic move is intended to enhance non-invasive, technology-driven solutions for managing chronic pain and addressing conditions such as diabetic peripheral neuropathy while improving technological capabilities and increasing market reach. NeuroMetrix, Inc. is a US-based healthcare company specializing in the development and commercialization of products designed to diagnose and treat diabetic peripheral neuropathy.

Major players in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grunenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.

North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic peripheral neuropathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic peripheral neuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic peripheral neuropathy market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical treatment services, and physical and occupational therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic peripheral neuropathy market also includes sales of pharmaceuticals, medical devices, nutritional supplements, and physical therapy tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Peripheral Neuropathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic peripheral neuropathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic peripheral neuropathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic peripheral neuropathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease: Type 2 Diabetic Peripheral Neuropathy; Type 1 Diabetic Peripheral Neuropathy
• 2) By Treatment: Pain Management Drugs; Gene Therapies
• 3) By Therapy: Antidepressants; Anticonvulsants
• 4) By Patient Population: Adult Patients; Geriatric Patients
• Subsegments:
• 1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy; Motor Neuropathy; Autonomic Neuropathy
• 2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyradiculopathy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc.; Eli Lilly and Company; Astellas Pharma Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Peripheral Neuropathy Market Characteristics

3. Diabetic Peripheral Neuropathy Market Trends And Strategies

4. Diabetic Peripheral Neuropathy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Peripheral Neuropathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Peripheral Neuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Peripheral Neuropathy Market Growth Rate Analysis
• 5.4. Global Diabetic Peripheral Neuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Peripheral Neuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Peripheral Neuropathy Total Addressable Market (TAM)

6. Diabetic Peripheral Neuropathy Market Segmentation

• 6.1. Global Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetic Peripheral Neuropathy
• Type 1 Diabetic Peripheral Neuropathy
• 6.2. Global Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Management Drugs
• Gene Therapies
• 6.3. Global Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants
• Anticonvulsants
• 6.4. Global Diabetic Peripheral Neuropathy Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult Patients
• Geriatric Patients
• 6.5. Global Diabetic Peripheral Neuropathy Market, Sub-Segmentation Of Type 2 Diabetic Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sensory Neuropathy
• Motor Neuropathy
• Autonomic Neuropathy
• 6.6. Global Diabetic Peripheral Neuropathy Market, Sub-Segmentation Of Type 1 Diabetic Peripheral Neuropathy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Distal Symmetric Neuropathy
• Mononeuropathy
• Polyradiculopathy

7. Diabetic Peripheral Neuropathy Market Regional And Country Analysis

• 7.1. Global Diabetic Peripheral Neuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Peripheral Neuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Peripheral Neuropathy Market

• 8.1. Asia-Pacific Diabetic Peripheral Neuropathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Peripheral Neuropathy Market

• 9.1. China Diabetic Peripheral Neuropathy Market Overview
• 9.2. China Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Peripheral Neuropathy Market

• 10.1. India Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Peripheral Neuropathy Market

• 11.1. Japan Diabetic Peripheral Neuropathy Market Overview
• 11.2. Japan Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Peripheral Neuropathy Market

• 12.1. Australia Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Peripheral Neuropathy Market

• 13.1. Indonesia Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Peripheral Neuropathy Market

• 14.1. South Korea Diabetic Peripheral Neuropathy Market Overview
• 14.2. South Korea Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Peripheral Neuropathy Market

• 15.1. Western Europe Diabetic Peripheral Neuropathy Market Overview
• 15.2. Western Europe Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Peripheral Neuropathy Market

• 16.1. UK Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Peripheral Neuropathy Market

• 17.1. Germany Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Peripheral Neuropathy Market

• 18.1. France Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Peripheral Neuropathy Market

• 19.1. Italy Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Peripheral Neuropathy Market

• 20.1. Spain Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Peripheral Neuropathy Market

• 21.1. Eastern Europe Diabetic Peripheral Neuropathy Market Overview
• 21.2. Eastern Europe Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Peripheral Neuropathy Market

• 22.1. Russia Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Peripheral Neuropathy Market

• 23.1. North America Diabetic Peripheral Neuropathy Market Overview
• 23.2. North America Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Peripheral Neuropathy Market

• 24.1. USA Diabetic Peripheral Neuropathy Market Overview
• 24.2. USA Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Peripheral Neuropathy Market

• 25.1. Canada Diabetic Peripheral Neuropathy Market Overview
• 25.2. Canada Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Peripheral Neuropathy Market

• 26.1. South America Diabetic Peripheral Neuropathy Market Overview
• 26.2. South America Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Peripheral Neuropathy Market

• 27.1. Brazil Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Peripheral Neuropathy Market

• 28.1. Middle East Diabetic Peripheral Neuropathy Market Overview
• 28.2. Middle East Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Peripheral Neuropathy Market

• 29.1. Africa Diabetic Peripheral Neuropathy Market Overview
• 29.2. Africa Diabetic Peripheral Neuropathy Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Peripheral Neuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Peripheral Neuropathy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Peripheral Neuropathy Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Peripheral Neuropathy Market Competitive Landscape
• 30.2. Diabetic Peripheral Neuropathy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Peripheral Neuropathy Market Other Major And Innovative Companies

• 31.1. Biogen Inc.
• 31.2. Vertex Pharmaceuticals Incorporated
• 31.3. Sun Pharmaceutical Industries Limited
• 31.4. Lupin Pharmaceuticals Inc.
• 31.5. Chemie Grunenthal GmbH
• 31.6. Alkem Laboratories Limited
• 31.7. Acorda Therapeutics Inc.
• 31.8. Mitsubishi Tanabe Pharma Corporation
• 31.9. NeuroMetrix Inc.
• 31.10. Regenacy Pharmaceuticals Inc.
• 31.11. Helixmith Co. Ltd.
• 31.12. Aptinyx Inc.
• 31.13. WinSanTor Inc.
• 31.14. Sonnet BioTherapeutics Holdings Inc.
• 31.15. OLYS Pharma Inc.

32. Global Diabetic Peripheral Neuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Peripheral Neuropathy Market

34. Recent Developments In The Diabetic Peripheral Neuropathy Market

35. Diabetic Peripheral Neuropathy Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Peripheral Neuropathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Peripheral Neuropathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Peripheral Neuropathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer